- Ocugen Inc. - Patient-Centric Biotechnology
At Ocugen, we are focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe
- Ocugen, Inc. (OCGN) Stock Price, News, Quote History . . .
Ocugen, Inc , a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health
- Ocugen, Inc. Announces U. S. FDA Clearance of - GlobeNewswire
Ocugen, Inc is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases and offer hope for patients across the
- Ocugen Announces Rare Pediatric Disease Designation Granted . . .
MALVERN, Pa , May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration (U S FDA) has granted Rare Pediatric Disease Designation (RPDD) for OCU410ST for the treatment of
- Ocugen Shares Rise on FDA Ruling for Genetic Eye Disorder . . .
Ocugen shares rose 6 2% in premarket trading after disclosing that the Food and Drug Administration cleared the investigational new drug amendment to initiate a Phase 2 3 pivot confirmatory trial
- Ocugen Kicking Off Pivotal Trial of Stargardt Disease Gene . . .
Ocugen has high hopes for the pivotal trial after OCU410ST showed promising activity in the GARDian trial In Phase I of that study, treatment with OCU410ST in one eye slowed lesion growth by 48 percent a year after treatment compared to the untreated eye
- Ocugen: Three Potential Gene-Therapy Filings By 2028
Ocugen Overview Ocugen Inc (NASDAQ:OCGN) is a clinical-stage biotechnology company developing an interesting pipeline of modifier gene therapies for rare inherited retinal diseases In particular
|